# DESCRIPTION

## GOVERNMENT FUNDING

- acknowledge government funding

## TECHNICAL FIELD

- introduce C9orf46 homolog and Plg-RKT

## BACKGROUND

- motivate plasminogen binding
- summarize cell surface proteolysis
- limitations of prior plasminogen receptors

## BRIEF SUMMARY OF THE INVENTION

- introduce Plg-RKT and its functions

## DETAILED DESCRIPTION OF THE INVENTION

### A. Definitions

- define key terms
- specify protein structures

### B. Polypeptides

- define Plg-RKT polypeptide
- describe Plg-RKT molecule structure
- specify Plg-RKT polypeptide embodiments
- describe conserved native epitope
- specify binding inhibition capacity
- list SEQ ID NOs
- define Plg-RKT polypeptides
- describe characteristics of Plg-RKT polypeptides
- explain analogs and derivatives of Plg-RKT polypeptides
- discuss modifications and linkers of Plg-RKT polypeptides
- outline synthesis and uses of Plg-RKT polypeptides

### C. Antibodies and Monoclonal Antibodies

- define antibody
- describe antibody combining site
- introduce antibody molecules
- characterize anti-Plg-RKT antibody
- describe antibody preparation methods
- introduce inoculum and polypeptide conjugation
- describe monoclonal antibody
- produce monoclonal antibody

### D. Diagnostic Systems

- define diagnostic system
- describe package contents
- explain instructions for use
- introduce label or indicating means
- describe linking of labels
- introduce specific binding agent
- describe ELISA format
- describe affixation of reagent to solid matrix
- introduce diagnostic methods for inflammation
- introduce diagnostic methods for cancer
- introduce diagnostic methods for hematologic disorders

### E. Assay Methods

- describe immunoassay methods for determining Plg-RKT in body fluid samples
- outline steps for forming an immunoreaction admixture and determining Plg-RKT polypeptide-containing immunoreaction product
- describe competitive and non-competitive assay methods
- outline methods for detecting Plg-RKT on cells from body fluid samples
- describe various diagnostic methods for detecting Plg-RKT expression

### F. Therapeutic Compositions

- describe therapeutic compositions containing Plg-RKT polypeptide, antibody, or monoclonal antibody as active ingredient
- outline preparation and composition of pharmacological compositions

### G. Therapeutic Methods

- describe method for blocking plasminogen, plasminogen fragments, tissue plasminogen activator or lipoprotein(a) binding to
- outline administration of therapeutically effective amount of Plg-RKT polypeptide, antibody, or monoclonal antibody
- describe determination of therapeutically effective amount of Plg-RKT polypeptide, antibody, or monoclonal antibody
- outline composition and administration of Plg-RKT polypeptide, antibody, or monoclonal antibody for therapeutic use

## EXAMPLES

- isolate Plg-RKT
- describe amino acid sequence of Plg-RKT
- determine cell and tissue distribution of Plg-RKT
- demonstrate plasminogen binding to carboxyl terminal peptide of Plg-RKT
- detect upregulation of Plg-RKT in membranes of M-CSF treated cells
- show partitioning of Plg-RKT to detergent phase
- generate monoclonal antibody that inhibits plasminogen binding to Plg-RKT
- design inhibitory Plg-RKT polypeptides
- demonstrate recognition of Plg-RKT by plasminogen fragments
- generate monoclonal antibody that distinguishes breast cancer cells from normal tissue

